OmniAb’s analyst price target remains unchanged at $7.33 per share. Analysts note that minor adjustments in profit margin and discount rate projections were not sufficient to alter their outlook on the company's value.
What's in the News
- OmniAb, Inc. and ArrowMark Partners have entered into a license and services agreement with Mabtrx Biosciences. This arrangement provides OmniAb with revenue, the potential for equity, and royalties related to novel antibody discoveries (Client Announcements).
- OmniAb has announced its 2025 earnings guidance, projecting revenue between $18 million and $22 million (Corporate Guidance).
- OmniAb closed a private placement on September 10, 2025, raising nearly $30 million from 15 investors and paying approximately $1.8 million in sales commission (Private Placements).
Valuation Changes
- Consensus Analyst Price Target remains unchanged at $7.33 per share.
- Discount Rate has risen slightly from 7.93% to 7.93%.
- Revenue Growth projection holds steady at 37.84%.
- Net Profit Margin has fallen slightly from 15.70% to 15.51%.
- Future P/E ratio has increased marginally from 187.12x to 189.38x.
Have other thoughts on OmniAb?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.